Last 778.15 INR
Change Today +26.90 / 3.58%
Volume 90.5K
CDH On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 06/18/13 All times are local (Market data is delayed by at least 15 minutes).

cadila healthcare ltd (CDH) Snapshot

Open
748.05
Previous Close
751.25
Day High
784.00
Day Low
748.00
52 Week High
11/26/12 - 975.00
52 Week Low
03/22/13 - 714.20
Market Cap
159.3B
Average Volume 10 Days
246.0K
EPS TTM
32.01
Shares Outstanding
204.7M
EX-Date
06/11/13
P/E TM
24.3x
Dividend
7.50
Dividend Yield
0.96%
Current Stock Chart for CADILA HEALTHCARE LTD (CDH)

Related News

No related news articles were found.

cadila healthcare ltd (CDH) Related Businessweek News

No Related Businessweek News Found

cadila healthcare ltd (CDH) Details

Cadila Healthcare Limited discovers, develops, manufactures, and markets a range of healthcare products worldwide. It provides API, formulations, animal health products, and cosmeceuticals. The company offers products in the areas of cardiovasculars, gastro intestinals, respiratory, women’s healthcare, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology, nephrology, and chronic/lifestyle primarily under the Aten, Ocid, Deriphyllin, Pantodac, Atorva, Nucoxia, and Mifegest brands. It also produces consumer healthcare and wellness products, such as Sugar Free Gold, a sweetener; Sugar Free Natura, a sucralose based sugar substitute; Sugar Free D’lite, a healthy drink; Nutralite, a cholesterol-free table spread; and Actilife, a nutritional milk additive for adults, as well as skincare products under its Everyuth and Dermacare brands. In addition, the company provides animal healthcare products comprising drugs, feed supplements, and vaccines for livestock, companion animals, and poultry. Further, it is involved in the research and development of new molecular entities, novel drug delivery systems, biologicals, and generic product development, as well as solid orals, pulmonary, parenterals, suppository, topical, and oncology products. The company was founded in 1952 and is headquartered in Ahmedabad, India.

Founded in 1952

cadila healthcare ltd (CDH) Top Compensated Officers

Chairman, Managing Director, Chairman of Comm...
Total Annual Compensation: 120.0M
Deputy Managing Director, Non Executive Direc...
Total Annual Compensation: 80.0M
Compensation as of Fiscal Year 2012.

cadila healthcare ltd (CDH) Key Developments

Cadila Healthcare Limited Declares Interim Dividend, Payable on or after June 17, 2013

Cadila Healthcare Ltd. announced its board of directors declared an interim dividend of INR 7.50 per equity share of INR 5 each for the year ended on March 31, 2013, at its meeting held on May 30, 2013. The board of directors has fixed June 12, 2013 as the record date for the determining the names of the shareholders entitled to receive the dividend. The dividend will be payable on or after June 17, 2013.

Cadila Healthcare Limited Reports Audited Consolidated and Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2013; Provides Capex Guidance for the Fiscal 2014

Cadila Healthcare Limited reported audited consolidated and standalone earnings results for the fourth quarter and year ended March 31, 2013. For the quarter, on a consolidated basis, the company reported total income from operations of INR 16,119.0 million against INR 13,980.0 million for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 2,398.3 million compared to INR 2,437.3 million a year ago. Profit from ordinary activities before tax was INR 2,170.0 million against INR 2,237.7 million for the same period last year. Net profit for the period was INR 2,753.0 million or INR 12.82 per basic and diluted share against INR 1,801.4 million or INR 8.35 per basic and diluted share for the same period last year. For the year, on a consolidated basis, the company reported total income from operations of INR 63,580.7 million against INR 52,633.1 million for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 9,428.5 million compared to INR 9,259.8 million a year ago. Profit from ordinary activities before tax was INR 8,112.2 million against INR 7,942.3 million for the same period last year. Net profit for the period was INR 6,917.3 million or INR 32.01 per basic and diluted share against INR 6,811.9 million or INR 31.87 per basic and diluted share for the same period last year. Earnings before interest, depreciation and tax, excluding the impact of onetime loss in income received in the previous year, was up by 9% to INR 11,255 million from INR 10,325 million last year. Net profit, excluding onetime income, was up by 7% to INR 6,551 million from INR 6,116 million last year. The consolidated debt, on a gross level, stood at INR 29,219 million. The consolidated capex for the year was INR 6,881 million. Capex on R&D included in this was INR 495 million. For the quarter, on a standalone basis, the company reported total income from operations of INR 9,539.6 million against INR 7,837.8 million for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 2,096.8 million compared to INR 1,527.8 million a year ago. Profit from ordinary activities before tax was INR 2,023.2 million against INR 1,475.1 million for the same period last year. Net profit for the period was INR 2,025.3 million or INR 9.89 per basic and diluted share against INR 1,394.0 million or INR 6.81 per basic and diluted share for the same period last year. For the year, on a standalone basis, the company reported total income from operations of INR 33,642.2 million against INR 31,507.8 million for the same period last year. Profit from operations before other income, finance costs and exceptional items was INR 5,029.9 million compared to INR 5,595.5 million a year ago. Profit from ordinary activities before tax was INR 4,685.3 million against INR 6,704.3 million for the same period last year. Net profit for the period was INR 4,666.4 million or INR 22.79 per basic and diluted share against INR 6,575.2 million or INR 32.11 per basic and diluted share for the same period last year. The company expects tax rate is to be around 15% for the next year. The company expects capex is to be INR 6,000 million in the fiscal 2014.

Cadila Healthcare Limited - Special Call

Cadila Healthcare Limited - Special Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDH:IN 778.15 INR +26.90

CDH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 2,131 INR -15.50
View Industry Companies
 

Industry Analysis

CDH

Industry Average

Valuation CDH Industry Range
Price/Earnings 21.9x
Price/Sales 2.3x
Price/Book 4.7x
Price/Cash Flow 17.1x
TEV/Sales 1.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CADILA HEALTHCARE LTD, please visit www.zyduscadila.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.